A PYMNTS Company

EU: EC approves GlaxoSmithKline’s acquisition of Pfizer’s Consumer Health Business

By  |  July 10, 2019
EU: EC approves GlaxoSmithKline’s acquisition of Pfizer’s Consumer Health Business

The European Commission has approved, under the EU Merger Regulation, the acquisition of Pfizer’s Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer’s topical pain management business carried out under the ThermaCare brand.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    GlaxoSmithKline (GSK) and Pfizer’s Consumer Health Business are both manufacturers and suppliers of a variety of consumer healthcare pharmaceuticals, which are typically available to patients without a prescription from a doctor and generally referred to as “over-the-counter” (OTC) pharmaceutical products.

    The Commission examined the effects of the proposed transaction on competition in the markets where the activities of the companies overlap.

    Based on the investigation, the Commission was concernedthat the acquisition would reduce competition for topical pain management products, possibly resulting in price increases in a number of EEA countries, including Austria, Germany, Ireland, Italy and the Netherlands.

    To address these concerns, the companies offered to divest Pfizer’s topical pain management business carried out under the ThermaCare brand globally. This includes all relevant assets that contribute to the current operation or are necessary to ensure the viability and competitiveness thereof.

    Full Content: Europa Press

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.